Adachi Y, Tamiya A, Taniguchi Y, et al. - Researchers conducted this retrospective study investigating the predictive factors for nivolumab response in patients with non-small cell lung cancer (NSCLC) with good performance status (PS) and those with poor PS. Pretreatment clinical data of 296 consecutive patients with NSCLC treated with nivolumab were obtained. Data revealed that the median age was 70 years; 206 patients were male; and good PS (PS 0-1) in 224. In patients with NSCLC treated with nivolumab, shorter PFS (progression-free survival) was reported in patients with good PS in correlation to following factors: never smoking, high C-reactive protein, liver metastasis, pleural effusion, and steroid administration; whereas longer PFS was reported in patients with poor PS in correlation with high advanced lung cancer inflammation index.